Shares of CTPartners Executive Search Inc. (CTP) surged 29% to $3.95 in early trading Thursday, putting them on track to extend their 2015 gain of 31%. The upside being attributed to news the company agreed to be acquired by DHR International. Pricing and other terms have not been disclosed, but the company indicated preliminary price range by DHR Int’l is below the $7.00 per share DHR previously proposed to pay in a Feb. 5, 2015 letter to the CTP board of directors.
Shares of Calithera Biosciences, Inc. (CALA) rocketed over 17% Thursday following reports of positive initial Phase I safety data for CB-839, used to treat Acute Leukemias.
“We are very encouraged by these early clinical data,” stated Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. “While the primary objectives of this study are to determine the safety and tolerability of CB-839, we were also able to demonstrate promising clinical activity including a complete response in the bone marrow, with incomplete recovery of peripheral counts (CRi) in one patient.”
Shares of Ampio Pharmaceuticals, Inc. (AMPE) are up more than 34% to $2.72 in early morning trading after the company announced positive results of its OptimEyes trial for the Treatment of Diabetic Macular Edema.
The OptimEyes trial, with FDA guidance, was designed to include a wide variety of DME patients, some of whom had no therapeutic options and were progressing to blindness.
Shares of FireEye, Inc. (FEYE) are currently printing intraday highs at $43.88 ahead of executive appearance on Cramer’s Mad Money tonight. The move comes on a strong volume too with the issue currently trading more than 2.3 million shares.
Currently there are 15 analysts that rate FEYE a ‘Buy’, 14 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. The name has a median Wall Street price target of $48.00 with a high target of $56.00.